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Abstract In-frame mutations were introduced into various 
portions of the human immunodeficiency virus type 1 (HIV-1) 
gag gene, and potentials of the mutants to suppress the 
replication of wild-type HIV-1 were monitored. In contrast to 
results obtained with matrix and nucleocapsid mutants, almost 
all capsid mutants blocked HIV-1 replication completely in 
single-round replication assays. A capsid mutant designated C6b 
was demonstrated to be one of the most efficient inhibitors for 
HIV-1 reported to date, and to be effective at both early and late 
viral replication phases. T-cells, which are engineered to express 
the C6b Gag in response to HIV-1 infection, were perfectly 
resistant to HIV-1. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Mutations can confer a dominant negative phenotype on 
viruses. When a gene carrying such a mutation is expressed, 
its product can dominantly interfere with the function nor-
mally accomplished by the product of the wild-type (wt) 
gene. When the gene product is multimeric, an effective dom-
inant negative mutant could be one that makes a monomer 
still capable of interacting with wt protein but is otherwise 
defective, and that could recruit wt monomers into non-func-
tional multimers. In such a case, only a moderate level of 
expression of the dominant negative mutant would be suffi-
cient to exert a strong inhibitory effect on the wt protein. At 
least three distinct HIV-1 genes, tat, rev, and gag, are poten-
tial targets for the generation of dominant negative mutants. 
In fact, dominant negative mutants of Tat, Rev, and Gag 
have been described [1-4]. Because of the highly multimerized 
state of Gag proteins in the mature virion, dominant negative 
mutants of Gag may be the most effective. However, a sys-
temic analysis of gag gene mutants with respect to their ability 
to interfere with the replication of wt virus and to the molec-
ular basis underlying this interference has not yet been carried 
out. Furthermore, no quantitative data on the efficiency of the 
inhibitory effect have been reported. 
*Corresponding author. Fax: (81) (886) 33-7080. 
To investigate the functions of HIV-1 Gag proteins, we 
have recently constructed a series of gag mutants by linker 
insertions. All 20 mutants generated carry in-frame mutations, 
and the mutations are scattering in the gag gene. Phenotypic 
characterization showed that these mutants are defective at 
various stages of the viral replication cycle (our unpublished 
results). Thus, our Gag mutants were good candidates to 
monitor the ¿raws-dominant negative property. For facilita-
tion of this analysis, the single-round replication assay re-
cently developed by us [5,6] was used. In this report, we 
present data on systemic and quantitative analysis of the in-
terfering potentials of the HIV-1 capsid, matrix, and nucleo-
capsid mutants. We also show the viral replication phase 
where the interference occurred. 
2. Materials and methods 
2.1. Cell culture and DNA transfection 
Human CD4+ lymphoid cell lines, A3.01 [7], CEMxl74 [8], and 
U937 [9], were maintained in RPMI 1640 medium supplemented 
with 10% heat-inactivated fetal bovine serum (FBS). A human colon 
carcinoma cell line, SW480 [10], was maintained in Dulbecco's modi-
fied Eagle medium supplemented with 10% heat-inactivated FBS. For 
transfection, uncleaved plasmid DNA was introduced into SW480 and 
lymphoid cells by the calcium phosphate co-precipitation [10] and 
modified DEAE-dextran [11] methods, respectively. To obtain 
G418-resistant stable lines, CEMxl74 cells were transfected with 
DNAs by the electroporation method [12]. 
2.2. CAT and RT assays 
The chloramphenicol acetyltransferase (CAT) and reverse transcrip-
tase assays have been previously described [13,14]. 
2.3. Single-round replication assay 
The process of HIV-1 replication was quantitatively analyzed by a 
system designated single-round replication assay (SRA) [5,6]. 
2.4. Western blotting 
Western immunoblotting was performed as previously described 
[14]. Specific viral Gag proteins were detected by the ECL 
system using a monoclonal antibody against HIV-1 Gag p24 (Amer-
sham). 
2.5. DNA constructs 
An infectious molecular clone of HIV-1 designated pNL432 has 
been described previously [10]. All in-frame gag gene mutants listed 
in Fig. 1 and Table 1 were constructed from pNL432 by linker in-
sertions. Mutations introduced into pNL432 were confirmed by nu-
cleotide sequencing. Rev-inducible Gag expression vectors designated 
pRgWT (wt) and pRgC6b (mutant) were constructed by cloning their 
parental gag (AssHII-iiwcII) and RRE (rev-responsive element) 
(Nhel-BamHl) sequences into pRVSVneo [15]. A Rev expression vec-
tor designated previ was previously described [5,6]. 
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Fig. 1. In-frame gag gene mutants of HIV-1 used in this study. Sites of mutations introduced are indicated by * . Small letters a and b indicate 
that Notl and Clal linkers (Takara), respectively, were used for mutagenesis except for C6b (Xhol linker). RT production in SW480 cells at 48 
h after transfection of each mutant (20 μg) is shown on the right. ++++, 90-110% of wt; +++, 50-70%; ++, 20-40%; +, < 10%. 
3. Results 
3.1. Generation of gag gene mutants 
A total of 20 gag gene mutants were constructed from 
pNL432 (Fig. 1 and Table 1). We employed scattered muta-
genesis by linker insertions (Fig. 1), and all mutations were in-
frame (Table 1) as confirmed by núcleo tide sequencing. The 
resultant mutants contained insertions of two to four amino 
acids, and some bore, in addition, substitutions of amino 
acids (Table 1). When transfected into SW480 cells [10], the 
mutants generated progeny virions as monitored by RT assay 
to varying degrees (Fig. 1). The effects of mutations were 
dependent on the positions of mutations, but not on the link-
ers used (thus, not on the amino acids). It appeared that the 
N-terminal portion of matrix pi7 and the C-terminal portion 
of capsid p24 are important for virion production (Fig. 1). 
3.2. Potentials of the gag mutants to suppress the replication of 
wt clone 
We recently developed a system designated SRA [5,6] for 
determination of the defective step of HIV-1 mutant. This 
system utilizes replication-defective rev(—) proviral clones car-
rying CAT (pNLnCAT etc.) and is dependent on trans-com-
plementation for production of infectious vector virus [5,6]. 
Simply by monitoring CAT activity in cells infected with this 
CAT virus, one round of viral replication cycle can be quan-
titatively estimated [5,6]. In this study, proviral wt and gag 
mutant clones instead of previ [5,6] were used as a Rev sup-
plier. 
SW480 cells were co-transfected with pNLnCAT and wt or 
mutant clones, and supernatants were harvested 2 days later. 
Equal volumes of the supernatants were inoculated into 
CD4+ A3.01 cells, and 3 days later, cells were harvested for 
the CAT assay. As shown in Fig. 2, the wt sample generated a 
very high level of CAT activity. A fair level of CAT was 
induced in cells infected with most of the matrix and nucleo-
tide mutants. In contrast, all capsid mutants, with one excep-
tion, inhibited CAT production almost completely. Essentially 
the same results were obtained in another lymphocytic cell 
line, CEMxl74, and a monocytic cell line, U937 (data not 
shown). One of the mutants with a high ability of inhibition, 
designated NL-C6b, was tested for its ability to interfere with 
Table 1 
Amino 
in this 
acid sequences of gag gene mutants of HIV-1 NL432 used 
study 
Mutants 
Mia 
Mlb 
M2a 
M2b 
M3a 
M3b 
Cla 
Clb 
C2a 
C2b 
( 5 7 ) C R ( 5 8 ) 
C R A A A R 
C S G R P R 
( 9 8 ) K E ( 9 9 ) 
K A A A K E 
K H R C K E 
( 1 1 8 ) A A A D ( 1 2 1 
A V A A A T D 
A A H R W A D 
( 1 5 2 ) L N A - - W(155) 
L K A A A W 
LNHRWW 
( 2 0 9 ) A A - - E ( 2 1 1 ) 
A A A A E 
A H R W E 
Mutants 
C3a 
C3b 
C4a 
C4b 
C5a 
C5b 
C6a 
C6b 
Nla 
N ib 
( 2 1 8 J V H A - - G ( 2 2 1 ) 
V S G R S G 
V P S M A G 
( 2 4 0 ) T S ( 2 4 1 ) 
T R R P P S 
T S I D A S 
( 2 8 0 ) T S I - - L ( 2 8 3 ) 
T R A A A L 
T S HRWL 
( 3 0 9 ) A S ( 3 1 0 ) 
A A A A A S 
A P R G A S 
( 4 0 5 ) C R A - - P ( 4 0 8 ) 
C R A A A P 
C S H R W P 
WT sequences are shown on the upper line. Figures in parentheses 
represent the amino acid numbers of NL432 Gag protein. 
Fig. 2. Inhibition of HIV-1 replication as monitored by SRA. 
SW480 cells were cotransfected with pNLnCAT (10 μg) and 
pNL432 or mutant clones (10 μg), and 2 days later, culture super-
natants were harvested. Equal volumes of the supernatants were in-
oculated into CD4+ A3.01 cells, and 3 days later, cells were har-
vested for CAT assay. The parental pNL432 and pUC19 were used 
as positive (WT) and negative (NegCR) controls, respectively. 
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Fig. 3. Expression of C6b in cells. A: Structure of Gag expression vector. The gag sequence is flanked by RSV promoter (RSVp) and SV40 
poly(A) signal (SV40pA). RRE sequence is placed between gag and SV40pA. Another expression unit of neo gene is present in the vector [15]. 
B: Western blotting analysis of cell lysates prepared from transfected SW480 cells. SW480 cells were transfected with pNL432 (a), pRgWT (c), 
pRgC6b (d), pRgWT plus previ (e), or pRgC6b plus previ (f); b, mock transfection. A monoclonal antibody against HIV-1 p24 was used to 
detect viral Gag proteins. The bands were visualized by the ECL system (Amersham). HIV-1 gag gene products p55 and p24 are indicated. C: 
Infection of G418-resistant CEMxl74 cells with HIV-1. CD4+ CEMxl74 cells were transfected with pRVSVneo (control) or pRgC6b, and cul-
tured in the presence of G418. Surviving cells were maintained and used for infection of HIV-1 RF strain. Only cells of positive control were 
productively infected with the RF strain (neo RF). Cells of negative control (mock infection; neo mock) and C6b(+) cells (C6b RF) gave no 
detectable virus after infection of HIV-1 RF. 
the replication of the wt clone in more detail. A dose-response 
relationship with regard to inhibition of the wt replication was 
determined by the same method described in Fig. 2. In the 
presence of more C6b than wt by only twofold, the replication 
of wt clone was actually completely blocked (data not shown). 
We next asked whether C6b can suppress the growth of wt 
HIV-1 in CD4 cells. For this purpose, Gag expression vectors 
designated pRgWT and pRgC6b were constructed (Fig. 3). 
The expression of the constructs was designed to be Rev-in-
ducible (Fig. 3A), since Gag might be more or less toxic for 
cells and should not be expressed without HIV infection. As 
clearly seen in Fig. 3B, Gag p55 was expressed only in the 
presence of Rev, and was really Rev-inducible. Cells which 
contain the C6b sequence in the genome were selected by 
G418 after electroporation of pRgC6b. The cells obtained 
were then infected with HIV-1 RF strain, and monitored for 
virus infection. Neither virus production nor viral CPE was 
observed (Fig. 3C). 
3.3. Stage in the viral replication cycle of the C6b mutant 
acting as a represser 
The critical phase of viral replication when C6b is effective 
for inhibition was determined by the SRA using pNLnCAT 
(proviral rev(—) reporter CAT construct) [5,6], previ (Rev 
expression vector) [5,6], pRgWT, and pRgC6b. As shown in 
Fig. 4A, no interference by C6b was detected in the process of 
transcription and translation as monitored by the first CAT 
assay [5,6]. In sharp contrast, virion production as monitored 
by the RT assay [5,6], and the proceeding of the early repli-
cation phase as monitored by the second CAT assay (from 
entry to DNA integration) [5,6], were greatly affected (Fig. 
4B,C). These inhibitory effects of C6b on the replication of 
the wt clone could account for the lack of productive viral 
infection in C6b(+) cells (Fig. 3C). 
4. Discussion 
In this study, we evaluated the ability of 20 gag gene mu-
tants to interfere with the replication of wt HIV-1. We dem-
onstrate here that the capsid mutants are very effective against 
HIV-1 replication (Fig. 2). More importantly, the observed 
inhibition was very efficient, and C6b would be better than 
the other Zrawi-dominant negative mutants previously re-
ported [1-3]. Of note is that a mass culture of cells, which 
had been transfected with pRgC6b, was perfectly resistant to 
HIV-1 infection. Without selection of particular cell clones 
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Fig. 4. Effective inhibitory stage in viral replication cycle of C6b. 
All the data presented were obtained by SRA described previously 
[5,6]. CAT (A) and RT (B) production in transfected cells is indica-
tive of a normal proceeding of the late replication phase (from tran-
scription and translation to virion release). The early phase of viral 
replication (from entry to viral DNA integration) can be monitored 
by measuring CAT activity (C) in cells infected with equal amounts 
of the CAT virus (1 X 105 RT units) obtained by transfection (B). 
CD4+ A3.01 cells were used throughout the experiments here. DNA 
clones used in (A) and (B), and viruses obtained from transfection 
and used in (C) are indicated on the lower right. 
which are highly resistant to the virus, no virus production 
was detected (Fig. 3C). Furthermore, C6b(+) cells would ex-
press the mutant Gag only after HIV-1 infection. 
The C6b Gag interfered with HIV-1 replication at both 
early and late phases (Fig. 4). Although the precise mecha-
nism underlying this result remains to be elucidated, it is quite 
reasonable to assume that wt and C6b Gag assemble into 
virions poorly, and that chimeric virions consisting of wt 
and C6b Gag are very ineffective to initiate infection. It is 
also possible that the late defect of the NL-C6b virus is the 
production of immature virions with poor RT activity. Our 
preliminary data suggest that the early defect of NL-C6b virus 
could be located at the process of uncoating/reverse transcrip-
tion. Further study is required to fully understand the func-
tion of HIV-1 Gag. 
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